Alpha Tau Net Income From Continuing Ops Over Time
| DRTSW Stock | USD 0.26 0.05 23.81% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Alpha Tau Performance and Alpha Tau Correlation. Alpha |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alpha Tau. If investors know Alpha will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alpha Tau listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.22) | Return On Equity (0.33) |
The market value of Alpha Tau Medical is measured differently than its book value, which is the value of Alpha that is recorded on the company's balance sheet. Investors also form their own opinion of Alpha Tau's value that differs from its market value or its book value, called intrinsic value, which is Alpha Tau's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alpha Tau's market value can be influenced by many factors that don't directly affect Alpha Tau's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alpha Tau's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alpha Tau is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alpha Tau's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income From Continuing Ops Analysis
Compare Alpha Tau Medical and related stocks such as ZyVersa Therapeutics, Sonnet Biotherapeutics, and Revelation Biosciences Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZVSA | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (8.1 M) | (14 M) | (89.6 M) | (85.1 M) |
| SONN | (5.3 M) | (5.3 M) | (5.3 M) | (5.7 M) | (5.7 M) | (14.5 M) | (7.2 M) | (7.2 M) | (7.2 M) | (17.4 M) | (25 M) | (29.7 M) | (18.8 M) | (17.4 M) | (18.3 M) |
| REVB | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 6.2 M | 8.8 M | 16.3 M | 27.6 M | 31.7 M | (12 M) | (12 M) | (10.8 M) | 875.1 K | 831.3 K |
| QNRX | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (2.1 M) | (21.5 M) | (9.4 M) | (8.6 M) | (9.1 M) |
| ALLR | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (5.1 M) | (26.6 M) | (16.1 M) | (13 M) | (13.7 M) |
| VRAX | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (672.9 K) | (1.7 M) | (5.5 M) | (6.7 M) | (6.4 M) |
| BDRX | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (22.2 M) | (5.5 M) | (7.7 M) | (7.1 M) | (7.4 M) |
| PALI | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (26.6 M) | (14.3 M) | (12.3 M) | (12.9 M) |
| UNCY | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.3 M) | (10 M) | (18.1 M) | (28.1 M) | (26.7 M) |
| IMMX | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (1.1 M) | (24.4 M) | (8.2 M) | (14.2 M) | (15 M) |
Alpha Tau Medical and related stocks such as ZyVersa Therapeutics, Sonnet Biotherapeutics, and Revelation Biosciences Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Alpha Tau Medical | DRTSW |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Israel |
| Exchange | NASDAQ Exchange |
USD 0.26
Additional Tools for Alpha Stock Analysis
When running Alpha Tau's price analysis, check to measure Alpha Tau's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alpha Tau is operating at the current time. Most of Alpha Tau's value examination focuses on studying past and present price action to predict the probability of Alpha Tau's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alpha Tau's price. Additionally, you may evaluate how the addition of Alpha Tau to your portfolios can decrease your overall portfolio volatility.